Form 4: Spero Therapeutics Executive Esther Rajavelu Reports Acquisition of 185,000 Shares of Common Stock

Esther Rajavelu, a key executive at Spero Therapeutics, has reported acquiring 185,000 shares of common stock through restricted stock units.

Summary

• Esther Rajavelu, Chief Executive Officer, Chief Financial Officer and Chief Business Officer of Spero Therapeutics, filed a Form 4 on May 6, 2025, reporting a transaction on May 2, 2025.
• Rajavelu acquired 185,000 shares of Spero Therapeutics common stock through restricted stock units (RSUs).
• These RSUs vest in four equal annual installments starting May 2, 2026, contingent upon continued service.
• Following the transaction, Rajavelu beneficially owns 909,720 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally a good sign, but it's part of a standard compensation package.

Positives

• The acquisition of shares by a key executive could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the RSUs is contingent upon the Reporting Person's continued service, suggesting a commitment to the company's future.

Industry Context

Insider transactions are closely monitored as they can provide insights into management's perspective on the company's valuation and future performance. This transaction is a routine disclosure of equity compensation.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a key executive.

Key Dates

Keywords

Spero Therapeutics, Form 4, insider trading, Esther Rajavelu, restricted stock units, SPRO, beneficial ownership